CRANFORD, N.J. The corporation that has acquired the Wyeth Pharmaceuticals drug product manufacturing and packaging plant in Rouses Point now has a new president. Alan L. Rubino, who has spent 30 years in the pharmaceutical industry, was appointed to the position with Akrimax Pharmaceuticals, according to a Feb. 25 press release. Mr. Robino served most recently as president and chief operating officer of the Pharmos Corporation, based in Iselin, N.J. He is credited with having led the transformation of the company through the acquisition of Vela Pharmaceuticals and subsequent restructuring of Pharmos to focus on its leading development compound, currently in Phase 2b clinical trials for the treatment of irritable bowel syndrome. Prior to joining Pharmos, Mr. Rubino spent 24 years at Hoffmann-La Roche, one of the worlds top 10 pharmaceutical companies and a global leader in the diagnostics sector, based in Switzerland. At Roche, Mr. Rubino was a corporate officer and member of the U.S. executive committee, holding a variety of key positions with broad management responsibilities in operations, marketing, business development, human resources and corporate strategy. We are thrilled that Alan has agreed to join Akrimax, said Akrimax co-founder and board of directors chairman Joseph J. Krivulka. His experience in building long-term value and strategic alliances with industry partners is exactly what we want. And his extensive industry knowledge will bring new opportunities for Akrimax and our customers. Mr. Rubino is credited for being accomplished in various therapeutic areas with comprehensive knowledge and product marketing experience in cardiovascular, central nervous system, oncology, gastroenterology, infectious diseases, dermatology and biotechnology. He now joins the senior management team that formed Akrimax late last year, which includes co-founder and vice chairman Leonard L. Mazur. The team purchased the 950,000-square-foot manufacturing facility in Rouses Point and select pharmaceutical products from Wyeth in January. Joining the Akrimax team is a great opportunity as they have a proven track record of building highly successful companies, Mr. Rubino stated. Akrimax is a fast-growing and ambitious new company and I look forward to being part of its development and growth as we become a major specialty pharma player that also possesses significant capabilities to be among the best strategic manufacturing partners in the industry. Akrimax and Wyeth are working under a cooperative relationship during the transition at the Rouses Point facility, which will conclude at the end of 2009. Akrimax is leasing the facility to Wyeth while the company continues to manufacture its products and Akrimax integrates its own products into the facility. Wyeth will transfer operation of the drug product manufacturing and packaging plant to Akrimax late next year, maintaining the existing workforce to develop, manufacture and distribute pharmaceutical products from its own portfolio and other third-party contracts, Mr. Krivulka has previously stated. Representatives from Akrimax Pharmaceuticals, including Mr. Rubino and Mr. Krivulka, will be guests of honor at an economic development breakfast forum at the Holiday Inn, 412 State Route 3, Plattsburgh, Thursday, March 13. The forum, hosted by the Plattsburgh-North Country Chamber of Commerce, will begin at 7:30 a.m. A presentation from Akrimax officials regarding the corporations future plans will include a question and answer period and opportunity to meeting Akrimax executives. Registration for the forum is $16 per person for chamber of commerce members and $30 for nonmembers. The cost will include a full breakfast buffet. For more information or to register, contact the chamber of commerce at 563-1000 or visit the chambers Web site at www.northcountrychamber.com.